demo

Prof Jianjun Wang was invited to attend Tigermed’s ASCO Pre-Event Webinar as a Speaker to present Qurgen’s breakthrough cell converting

No infusion related reactions (IRRs) were observed in patients enrolled in the ongoing Qurgen Clinical trial using a 48-hour continuous

Qurgen reported that numbers of patients with advanced solid tumors had received low-dose SON-DP treatment (2-4.5 mg/kg) for over 18

Qurgen has expanded the clinical trial of its cell-converting cancer therapy in the following four clinical sites.